Search Orphan Drug Designations and Approvals
-
| Generic Name: | Varicella Zoster Immune Globulin (Human) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | VARIZIG | ||||||||||||||||
| Date Designated: | 11/07/2006 | ||||||||||||||||
| Orphan Designation: | Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Cangene bioPharma, Inc. 155 Innovation Drive Winnipeg Canada The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | Varicella Zoster Immune Globulin (Human) |
|---|---|---|
| Trade Name: | VARIZIG | |
| Marketing Approval Date: | 12/20/2012 | |
| Approved Labeled Indication: | Post exposure prophylaxis of varicella in high risk individuals to reduce the severity of varicella | |
| Exclusivity End Date: | 12/20/2019 | |
| Exclusivity Protected Indication* : | ||
-
